Insilico Medicine's Lilly Deal Shifts the AI Drug Discovery Conversation
The Insilico-Lilly deal and INS018's Phase 3 entry are forcing a harder question: whether AI drug discovery validates itself through partnerships or through patients.
The Insilico-Lilly deal and INS018's Phase 3 entry are forcing a harder question: whether AI drug discovery validates itself through partnerships or through patients.
You've read 10 of 10 free stories this month. Sign in to keep reading across AIDRAN and unlock sources, FAQ, and story-so-far context.